METHODS AND KITS FOR DETECTING ADENOMAS, COLORECTAL CANCER, AND USES THEREOF

• US 20140171339A1
• Filed: 06/06/2012
• Published: 06/19/2014
• Est. Priority Date: 06/06/2011
• Status: Abandoned Application

• Current Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Original Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Inventors: Keku, Temitope, Fodor, Anthony, Sanapareddy, Nina
• Application Number:
  US14/124,443
• Publication Number:
  US 20140171339A1
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: C12Q 1/04 Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor C12Q1/6897 takes precedence
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 1/689 for bacteria
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/57419 of colon

Abstract

This invention is directed to a novel method to detect adenomas and colorectal cancer (CRC) using a bacterial signature. Included in the invention are methods of (a) determining an individual'"'"'s risk developing adenomas or CRC; (b) determine whether or not a patient should have a colonoscopy; (c) differential diagnosis; (d) staging; (e) selecting therapies; (f) monitoring therapies; (g) patient surveillance; and (h) drug screening. Kits and reagents for detecting adenomas and CRC and/or drug screening are also part of the invention.

Claims

1. A method for detecting colorectal adenoma in a patient which comprises:

(a) obtaining a suitable patient sample;

(b) measuring a level of five or more bacteria selected from a group consisting of Acidovorax, Acinetobacter, Agrobacterium, Akkermansia, Alistipes, Allobaculum, Aquabacterium, Azonexus, Bacillaceae_—

1, Bryantella, Carnobacteriaceae_—

1, Chryseobacterium, Chryseomonas, Cloacibacterium, Comamonas, Dechloromonas, Delftia, Enterobacter, Erwinia, Exiguobacterium, Flavimonas, Fusobacterium, Gp1, Gp2, Helicobacter, Lactobacillus, Lactococcus, Leuconostoc, Methylobacterium, Micrococcineae, Novosphingobium, Pantoea, Pseudomonas, Pseudoxanthomonas, Roseburia, Rubrobacterineae, Serratia, Shinella, Sphingobium, Staphylococcus, Stenotrophomonas, Succinivibrio, Sutterella, Syntrophococcus, Turicibacter, Variovorax, and Weissella; and

(c) comparing the patient sample levels with levels associated with a control sample, wherein elevated levels are indicative of whether or not colorectal adenoma is present or absent in the patient.

2. The method of claim 1, wherein the bacteria are selected from the group consisting of Acidovorax, Acinetobacter, Aquabacterium, Azonexus, Cloacibacterium, Dechloromonas, Delftia, Fusobacterium, Helicobacter, Lactobacillus, Lactococcus, Leuconostoc, Sphingobium, Stenotrophomonas, Succinivibrio, Turicibacter, and Weissella.

3. The method of claim 1, further comprising measuring levels of Bacteroides, Bifidobacteriaceae, Dorea, or Streptococcus, wherein decreased levels of Bacteroides, Bifidobacteriaceae, Dorea, or Streptococcus, are indicative of whether or not adenoma is present or absent in the patient.

4. The method of claim 1, wherein the bacteria levels are measured using bacterial nucleic acids.

5. The method of claim 4, wherein the bacterial nucleic acids are 16S rRNA genes.

6. The method of claim 4, wherein the bacterial nucleic acids are measured using terminal restriction fragment length polymorphism (T-RFLP).

7. The method of claim 4, wherein the bacterial nucleic acids are measured by fluorescence in-situ hybridization (FISH).

8. The method of claim 4, wherein the bacterial nucleic acids are measured by polymerase chain reaction (PCR).

9. The method of claim 4, wherein the bacterial nucleic acids are measured by pyrosequencing.

10. The method of claim 4, wherein the bacterial nucleic acids are measured by a microarray.

11. The method of claim 1, wherein the bacteria in the patient sample are cultured prior to measuring the levels.

12. The method of claim 1, wherein the bacteria levels are measured using antibodies.

13. The method of claim 1, wherein the patient sample is a fecal sample.

14. The method of claim 1, wherein the patient sample is a biopsy sample.

15. The method of claim 14, wherein the biopsy sample is a mucosal biopsy sample.

16. The method of claim 1, wherein the patient sample is a sample obtained by a rectal swab.

17. The method of claim 1, wherein the colorectal adenoma is an adenocarcinoma.

18. A method for determining whether or not a patient should have a colonoscopy which comprises:

(a) obtaining a suitable patient sample;

(b) measuring a level of five or more bacteria selected from a group consisting of Acidovorax, Acinetobacter, Agrobacterium, Akkermansia, Alistipes, Allobaculum, Aquabacterium, Azonexus, Bacillaceae_—

1, Bryantella, Carnobacteriaceae_—

1, Chryseobacterium, Chryseomonas, Cloacibacterium, Comamonas, Dechloromonas, Delftia, Enterobacter, Erwinia, Exiguobacterium, Flavimonas, Fusobacterium, Gp1, Gp2, Helicobacter, Lactobacillus, Lactococcus, Leuconostoc, Methylobacterium, Micrococcineae, Novosphingobium, Pantoea, Pseudomonas, Pseudoxanthomonas, Roseburia, Rubrobacterineae, Serratia, Shinella, Sphingobium, Staphylococcus, Stenotrophomonas, Succinivibrio, Sutterella, Syntrophococcus, Turicibacter, Variovorax, and Weissella; and

(c) comparing the patient sample levels with levels associated with a control sample, wherein elevated levels are indicative of whether or not the patient should have a colonoscopy.

19. A method for monitoring a patient for colorectal adenoma recurrence which comprises:

(a) obtaining a suitable patient sample;

(b) measuring a level of five or more bacteria selected from a group consisting of Acidovorax, Acinetobacter, Agrobacterium, Akkermansia, Alistipes, Allobaculum, Aquabacterium, Azonexus, Bacillaceae_—

1, Bryantella, Camobacteriaceae_—

1, Chryseobacterium, Chryseomonas, Cloacibacterium, Comamonas, Dechloromonas, Delftia, Enterobacter, Erwinia, Exiguobacterium, Flavimonas, Fusobacterium, Gp1, Gp2, Helicobacter, Lactobacillus, Lactococcus, Leuconostoc, Methylobacterium, Micrococcineae, Novosphingobium, Pantoea, Pseudomonas, Pseudoxanthomonas, Roseburia, Rubrobacterineae, Serratia, Shinella, Sphingobium, Staphylococcus, Stenotrophomonas, Succinivibrio, Sutterella, Syntrophococcus, Turicibacter, Variovorax, and Weissella; and

(c) comparing the patient sample levels with levels associated with appropriate controls, wherein elevated levels are indicative of adenoma recurrence in the patient.

20. A method for monitoring the progress of a treatment protocol for a patient which comprises:

(a) obtaining a suitable patient sample;

(b) measuring a level of five or more bacteria selected from group consisting of Acidovorax, Acinetobacter, Agrobacterium, Akkermansia, Alistipes, Allobaculum, Aquabacterium, Azonexus, Bacillaceae_—

1, Bryantella, Camobacteriaceae_—

1, Chryseobacterium, Chryseomonas, Cloacibacterium, Comamonas, Dechloromonas, Delftia, Enterobacter, Erwinia, Exiguobacterium, Flavimonas, Fusobacterium, Gp1, Gp2, Helicobacter, Lactobacillus, Lactococcus, Leuconostoc, Methylobacterium, Micrococcineae, Novosphingobium, Pantoea, Pseudomonas, Pseudoxanthomonas, Roseburia, Rubrobacterineae, Serratia, Shinella, Sphingobium, Staphylococcus, Stenotrophomonas, Succinivibrio, Sutterella, Syntrophococcus, Turicibacter, Variovorax, and Weissella; and

(c) comparing the patient sample levels with levels associated with appropriate controls, wherein modulated levels are indicative of the progress of the treatment for the patient.

21. A kit for detecting colorectal adenoma in a patient sample which comprises:

(a) a means for measuring a level of five more bacteria selected from a group consisting of Acidovorax, Acinetobacter, Agrobacterium, Akkermansia, Alistipes, Allobaculum, Aquabacterium, Azonexus, Bacillaceae_—

1, Bryantella, Carnobacteriaceae_—

1, Chryseobacterium, Chryseomonas, Cloacibacterium, Comamonas, Dechloromonas, Delftia, Enterobacter, Erwinia, Exiguobacterium, Flavimonas, Fusobacterium, Gp1, Gp2, Helicobacter, Lactobacillus, Lactococcus, Leuconostoc, Methylobacterium, Micrococcineae, Novosphingobium, Pantoea, Pseudomonas, Pseudoxanthomonas, Roseburia, Rubrobacterineae, Serratia, Shinella, Sphingobium, Staphylococcus, Stenotrophomonas, Succinivibrio, Sutterella, Syntrophococcus, Turicibacter, Variovorax, and Weissella; and

(b) instructions for comparing the patient sample levels with levels associated with healthy patient controls, wherein elevated levels are indicative of whether or not colorectal adenoma is present or absent in the patient.

22. A kit comprising:

(a) a reagent selected from a group consisting of;

(i) nucleic acid probes capable of specifically hybridizing with nucleic acids from five or more bacteria selected from a group consisting of Acidovorax, Acinetobacter, Agrobacterium, Akkermansia, Alistipes, Allobaculum, Aquabacterium, Azonexus, Bacillaceae_—

1, Bryantella, Carnobacteriaceae_—

1, Chryseobacterium, Chryseomonas, Cloacibacterium, Comamonas, Dechloromonas, Delftia, Enterobacter, Erwinia, Exiguobacterium, Flavimonas, Fusobacterium, Gp1, Gp2, Helicobacter, Lactobacillus, Lactococcus, Leuconostoc, Methylobacterium, Micrococcineae, Novosphingobium, Pantoea, Pseudomonas, Pseudoxanthomonas, Roseburia, Rubrobacterineae, Serratia, Shinella, Sphingobium, Staphylococcus, Stenotrophomonas, Succinivibrio, Sutterella, Syntrophococcus, Turicibacter, Variovorax, and Weissella;

(ii) a pair of nucleic acid primers capable of PCR amplification of five or more said bacteria; and

(iii) four or more antibodies specific for said bacteria; and

(b) instructions for use in measuring levels in a tissue sample from a patient suspected of having colorectal adenoma.

23. A method of identifying a compound that prevents or treats colorectal adenomas, the method comprising the steps of:

(a) contacting a tissue or an animal model with a compound;

(b) measuring a level of four or more bacteria selected from group consisting of Acidovorax, Acinetobacter, Agrobacterium, Akkermansia, Alistipes, Allobaculum, Aquabacterium, Azonexus, Bacillaceae_—

1, Bryantella, Carnobacteriaceae_—

1, Chryseobacterium, Chryseomonas, Cloacibacterium, Comamonas, Dechloromonas, Delftia, Enterobacter, Erwinia, Exiguobacterium, Flavimonas, Fusobacterium, Gp1, Gp2, Helicobacter, Lactobacillus, Lactococcus, Leuconostoc, Methylobacterium, Micrococcineae, Novosphingobium, Pantoea, Pseudomonas, Pseudoxanthomonas, Roseburia, Rubrobacterineae, Serratia, Shinella, Sphingobium, Staphylococcus, Stenotrophomonas, Succinivibrio, Sutterella, Syntrophococcus, Turicibacter, Variovorax, and Weissella; and

(c) determining a functional effect of the compound on the bacteria levels, thereby identifying a compound that prevents or treats colorectal adenomas.